Our study revealed that IGFBP-1 is a circulating growth factor independently associated with the occurrence of MACE over two years of follow-up among patients with PAD, highlighting its potential role as a biomarker for systemic atherosclerosis progression. This evidence concerns the gene IGFBP1 and atherosclerosis.